decisionhealth Newsletters, Coder Pink Sheets - 2005 Issue 7 (July)
Fecal DNA stool test is promising, but few are paying just yet
Subscribe or sign in to view the full article.
Article Overview
This article discusses the early clinical promise of fecal DNA stool testing for colorectal cancer screening and the payer environment surrounding it. It focuses on how Medicare and private payers viewed the test at the time, the general reimbursement outlook, and the coding references associated with billing the service. It is relevant to coders, billers, compliance staff, and revenue cycle professionals tracking emerging diagnostic tests and coverage policy.
Why This Topic Matters
Understanding the article helps readers see how an emerging colorectal cancer screening technology was being handled by payers and what coding references were being discussed for billing purposes. It also highlights the gap that can exist between clinical interest and reimbursement adoption.
What You Will Learn
- How fecal DNA stool testing was being positioned for colorectal cancer screening
- Why payer coverage status was a key issue for adoption
- What general billing and coding references were associated with the test
- How the article frames the relationship between newer screening tests and established colonoscopy-based evaluation
Who Should Read This
- Medical coders
- Medical billers
- Revenue cycle staff
- Compliance professionals
- Payer policy analysts
- Gastroenterology practices
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com